{"organizations": [], "uuid": "48f67935c892ef0fe949f605f2f2f24e3d6b380d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-astrazeneca-presents-new-data-eval/brief-astrazeneca-presents-new-data-evaluating-safety-and-efficacy-of-farxiga-idUSFWN1R10T3", "country": "US", "domain_rank": 408, "title": "BRIEF-Astrazeneca Presents New Data Evaluating Safety And Efficacy Of Farxiga", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-19T18:23:00.000+02:00", "replies_count": 0, "uuid": "48f67935c892ef0fe949f605f2f2f24e3d6b380d"}, "author": "", "url": "https://www.reuters.com/article/brief-astrazeneca-presents-new-data-eval/brief-astrazeneca-presents-new-data-evaluating-safety-and-efficacy-of-farxiga-idUSFWN1R10T3", "ord_in_thread": 0, "title": "BRIEF-Astrazeneca Presents New Data Evaluating Safety And Efficacy Of Farxiga", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "efficacy of farxiga reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "astrazeneca plc", "sentiment": "none"}, {"name": "astrazeneca", "sentiment": "none"}, {"name": "aes", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 19, 2018 / 4:23 PM / in 24 minutes BRIEF-Astrazeneca Presents New Data Evaluating Safety And Efficacy Of Farxiga Reuters Staff 1 Min Read March 19 (Reuters) - Astrazeneca Plc: * ASTRAZENECA PRESENTS NEW DATA EVALUATING SAFETY AND EFFICACY OF FARXIGA IN PATIENTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT * ASTRAZENECA - STUDY MET ITS PRIMARY AND SECONDARY EFFICACY ENDPOINTS * ASTRAZENECA - MEAN EGFR WAS DECREASED AT 24 WEEKS WITH DAPAGLIFLOZIN VERSUS PLACEBO IN STUDY * ASTRAZENECA - OVERALL, ADVERSE EVENTS OCCURRED IN 41.9% OF PATIENTS WITH DAPAGLIFLOZIN AND 47.8% WITH PLACEBO IN STUDY * ASTRAZENECA - AES RELATED TO STUDY TREATMENT BY INVESTIGATORS WERE REPORTED IN 10.6% OF PATIENTS WITH DAPAGLIFLOZIN AND 6.2% WITH PLACEBO * ASTRAZENECA - NO AES OF BONE FRACTURE OR AMPUTATION WERE REPORTED IN STUDY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-19T18:23:00.000+02:00", "crawled": "2018-03-19T18:35:48.005+02:00", "highlightTitle": ""}